<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">rsp</journal-id><journal-title-group><journal-title xml:lang="ru">Научно-практическая ревматология</journal-title><trans-title-group xml:lang="en"><trans-title>Rheumatology Science and Practice</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1995-4484</issn><issn pub-type="epub">1995-4492</issn><publisher><publisher-name>IMA-PRESS, LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.47360/1995-4484-2021-335-343</article-id><article-id custom-type="elpub" pub-id-type="custom">rsp-3044</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ПЕДИАТРИЧЕСКАЯ РЕВМАТОЛОГИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>PEDIATRIC RHEUMATOLOGY</subject></subj-group></article-categories><title-group><article-title>Клинико-фармакологические особенности течения ювенильного идиопатического артрита у 170 пациентов с полной и неполной вакцинацией против кори, паротита, краснухи и дифтерии: результаты проспективного пилотного исследования</article-title><trans-title-group xml:lang="en"><trans-title>The main factors, associated with incomplete vaccination againts measels, parotitis, rubella, and diphtheria in 170 juvenile idiopathic arthritis patients: the results of prospective pilot study</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-5782-8373</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Любимова</surname><given-names>Н. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Lybimova</surname><given-names>N. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>197341, Санкт-Петербург, ул. Аккуратова, 2</p></bio><bio xml:lang="en"><p>197341, Saint Petersburg, Akkuratova str., 2</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-2633-491X</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Фридман</surname><given-names>И. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Fridman</surname><given-names>I. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>197022, Санкт-Петербург, ул. Профессора Попова, 13</p></bio><bio xml:lang="en"><p>197022, Saint Petersburg, Professor Popov str., 13</p></bio><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-3285-9699</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Голева</surname><given-names>О. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Goleva</surname><given-names>O. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>197022, Санкт-Петербург, ул. Профессора Попова, 13</p></bio><bio xml:lang="en"><p>197022, Saint Petersburg, Professor Popov str., 13</p></bio><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-2371-2460</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Харит</surname><given-names>С. М.</given-names></name><name name-style="western" xml:lang="en"><surname>Kharit</surname><given-names>S. M.</given-names></name></name-alternatives><bio xml:lang="ru"><p>197022, Санкт-Петербург, ул. Профессора Попова, 13; 194100, Санкт-Петербург, ул. Литовская, 2</p></bio><bio xml:lang="en"><p>197022, Saint Petersburg, Professor Popov str., 13; 194100, Saint Petersburg, Litovskaya str., 2</p></bio><xref ref-type="aff" rid="aff-3"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-1180-8086</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Костик</surname><given-names>М. М.</given-names></name><name name-style="western" xml:lang="en"><surname>Kostik</surname><given-names>M. M.</given-names></name></name-alternatives><bio xml:lang="ru"><p>194100, Санкт-Петербург, ул. Литовская, 2</p></bio><bio xml:lang="en"><p>194100, Saint Petersburg, Litovskaya str., 2</p></bio><email xlink:type="simple">kost-mikhail@yandex.ru</email><xref ref-type="aff" rid="aff-4"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru">ФГБУ «Национальный медицинский исследовательский центр им. В.А. Алмазова» Минздрава России<country>Россия</country></aff><aff xml:lang="en">Almazov National Medical Research Centre<country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru">ФГБУ «Детский научно-клинический центр инфекционных болезней Федерального медико-биологического агентства»<country>Россия</country></aff><aff xml:lang="en">Pediatric Research and Clinical Center for Infectious Diseases under the Federal Medical Biological Agency<country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-3"><aff xml:lang="ru">ФГБУ «Детский научно-клинический центр инфекционных болезней Федерального медико-биологического агентства»;&#13;
ФГБОУ ВО «Санкт-Петербургский государственный педиатрический медицинский университет» Минздрава России<country>Россия</country></aff><aff xml:lang="en">Pediatric Research and Clinical Center for Infectious Diseases under the Federal Medical Biological Agency;&#13;
Saint-Petersburg State Pediatric Medical University<country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-4"><aff xml:lang="ru">ФГБОУ ВО «Санкт-Петербургский государственный педиатрический медицинский университет» Минздрава России<country>Россия</country></aff><aff xml:lang="en">Saint-Petersburg State Pediatric Medical University<country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2021</year></pub-date><pub-date pub-type="epub"><day>14</day><month>07</month><year>2021</year></pub-date><volume>59</volume><issue>3</issue><fpage>335</fpage><lpage>343</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Любимова Н.А., Фридман И.В., Голева О.В., Харит С.М., Костик М.М., 2021</copyright-statement><copyright-year>2021</copyright-year><copyright-holder xml:lang="ru">Любимова Н.А., Фридман И.В., Голева О.В., Харит С.М., Костик М.М.</copyright-holder><copyright-holder xml:lang="en">Lybimova N.A., Fridman I.V., Goleva O.V., Kharit S.M., Kostik M.M.</copyright-holder><license license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://rsp.mediar-press.net/rsp/article/view/3044">https://rsp.mediar-press.net/rsp/article/view/3044</self-uri><abstract><sec><title>Актуальность</title><p>Актуальность. Пациенты с ювенильным идиопатическим артритом (ЮИА) после выявления заболевания, как правило, имеют медицинский отвод от возрастных прививок (ревакцинаций), что приводит к снижению защитных поствакцинальных антител.</p><p>Цель исследования – изучить взаимосвязь особенности течения ювенильного идиопатического артрита у детей с полным и неполным комплексом возрастных вакцинаций против кори, паротита, краснухи и дифтерии.</p></sec><sec><title>Материалы и методы</title><p>Материалы и методы. В проспективное пилотное исследование были включены данные 170 детей (55 мальчиков и 115 девочек) в возрасте от 2 до 17 лет с диагнозом ЮИА, ранее получавших вакцинацию против кори, краснухи, паротита (ККП) и дифтерии. У всех пациентов методом иммуноферментного анализа определяли уровни поствакцинальных IgG-антител. В зависимости от наличия вакцинаций и ревакцинаций пациенты были разделены на две группы: пациенты с полной и неполной вакцинацией. Под неполной вакцинацией понималось меньшее число введения вакцин для данной возрастной группы в соответствии с Национальным календарем профилактических прививок. Данные представлены в виде отношения шансов (ОШ) и 95% доверительного интервала (ДИ).</p></sec><sec><title>Результаты</title><p>Результаты. Неполный комплекс вакцин против ККП выявлен у 50 детей старше 6 лет (32,5%). Неполный комплекс вакцин против дифтерии имел место у 6/16 (37,5%) детей младше 6 лет, у 53/110 (48,2%) детей в возрасте 6–14 лет и у 26/44 (59,1%) детей старше 14 лет. Основными предикторами неполной вакцинации против ККП были: возраст дебюта &lt;4 лет (отношение шансов (OШ) – 12,2 [5,0-28.9]; p=0,0000001); продолжительность ЮИА &gt;3 лет (OШ=4,4 [2,0- 9,9]; p=0,0002); продолжительность терапии метотрексатом &gt;3 лет (OШ=5,7 [2,7- 12,0]; p=0,000001); терапия генно-инженерными биологическими препаратами (ГИБП) (OШ=2,5 [1,3- 4,9]; p=0,008); лечение &gt;1 ГИБП (OШ=3,3 [1,1-10,4]; p=0,002). Основными предикторами неполной вакцинации против дифтерии были следующие: продолжительность ЮИА &gt;3 лет (OШ=3,4 [1,8- 6,5]; p=0,0002); длительность терапии метотрексатом &gt;2,8 года (OШ=4,1 [2,1-8,1]; p=0,00004); терапия ГИБП (OШ=2,4 [1,3-4,4]; p=0,006). В множественной регрессии только возраст начала ЮИА (p=0,00001) и продолжительность лечения метотрексатом (p=0,003) были предикторами неполной вакцинации против ККП; продолжительность лечения метотрексатом (р=0,005) и ГИБТ (р=0,05) – предикторами неполной вакцинации против дифтерии.</p></sec><sec><title>Выводы</title><p>Выводы. Неполная вакцинация у детей с ЮИА ассоциирована с более ранним возрастом дебюта и применением иммуносупрессивной терапии, что отражает отношение врачей и родителей пациентов к вакцинации детей с ревматическими заболеваниями. Требуются дальнейшие исследования, направленные на изучение безопасности вакцин у детей с ревматическими заболеваниями, что может изменить сложившиеся предубеждения против вакцинации.</p></sec></abstract><trans-abstract xml:lang="en"><sec><title>Background</title><p>Background. Patients with juvenile idiopathic arthritis (JIA) may have incomplete vaccination againts different vaccines leads to lower protective levels of anti-vaccine antibodies.</p><p>The aim of the study – to evaluate the rate and the main factors of incomplete vaccination against measels, parotitis, rubella (MMR), and diphtheria in JIA patients.</p></sec><sec><title>Methods</title><p>Methods. In the present study were included data 170 JIA (55 boys and 115 girls) aged from 2 to 17 years, who received scheduled vaccination before the age of 2 years and before JIA onset against measles, parotitis, diphtheria and rubella. Incomplete vaccination means the reduced number of vaccine to age. In all patients the IgG anti-vaccine antibodies levels were detected with ELISA. Data presented with odds ratio ()OR) with 95 confidence interval (CI).</p></sec><sec><title>Results</title><p>Results. Incomplete vaccination against MMR was in 50 (32.5%) of children less than 6 years. Incomplete vaccination against diphtheria was in 6/16 (37.5%) of children less than 6 year, in 53/110 (48.2%) of children aged 6–14 years and in 26/44 (59.1%) of the JIA patients more than 14 years. The main predictors in logistic regression for incomplete vaccination for MMR were: onset age &lt;4 years (OR=12.2 [95% CI: 5.0–28.9]; p=0.0000001), JIA duration &gt;3.1 years (OR=4.4 [95% CI: 2.0–9.9]; p=0.0002), methotrexate duration &gt;3 years (OR=5.7 [95% CI 2.7–12.0]; p=0.0000012); biologic treatment (OR=2.5 [95% CI: 1.3–4.9]; p=0.008) and treatment &gt;1 biologic (OR=3.3 [95% CI: 1.1–10.4]; p=0.002); for diphtheria were: JIA duration &gt;3.1 years (OR=3.4 [95% CI: 1.8–6.5]; p=0.0002), methotrexate duration &gt;2.8 years (OR=4.1 [95% CI: 2.1–8.1]; p=0.00004), biologic treatment (OR=2.4 [95% CI: 1.3–4.4]; p=0.006). In the multiple regression only JIA onset age (p=0.00001) and duration of methotrexate (p=0.003) were predictors of incomplete vaccination against MMR. Methotrexate duration (p=0.005) and biologics treatment (p=0.05) were predictors of incomplete vaccination against diphtheria.</p></sec><sec><title>Conclusion</title><p>Conclusion. The main predictor of incomplete vaccination was younger onset age of JIA. Children received more intensive immunosupression usually have scheduled vaccination rarely which leads to increased number of patients without protective antibody levels. These facts indicate the attitude of physicians parents to vaccination in immunocompromised children. Further investigations required for assessment of safety of vaccinations in children with rheumatic diseases may be a factor for changing this prejudice.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>ювенильный идиопатический артрит</kwd><kwd>вакцины</kwd><kwd>неполный комплекс вакцинации</kwd><kwd>корь</kwd><kwd>краснуха</kwd><kwd>эпидемический паротит</kwd><kwd>дифтерия</kwd></kwd-group><kwd-group xml:lang="en"><kwd>juvenile idiopathic arthritis</kwd><kwd>vaccines</kwd><kwd>incomplete vaccination complex</kwd><kwd>measles</kwd><kwd>rubella</kwd><kwd>mumps</kwd><kwd>diphtheria</kwd></kwd-group><funding-group xml:lang="ru"><funding-statement>Исследование поддержано грантом РФФИ № 18-515- 57001. Авторы несут полную ответственность за предоставление окончательной версии рукописи в печать.</funding-statement></funding-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Breda L, Del Torto M, De Sanctis S, Chiarelli F. Biologics in children’s autoimmune disorders: Efficacy and safety. Eur J Pediatr. 2011;170:15767. doi: 10.1007/s00431-010-1238-z</mixed-citation><mixed-citation xml:lang="en">Breda L, Del Torto M, De Sanctis S, Chiarelli F. Biologics in children’s autoimmune disorders: Efficacy and safety. Eur J Pediatr. 2011;170:15767. doi: 10.1007/s00431-010-1238-z</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Mayerl C, Prelog M. Immunosenescence and juvenile idiopathic arthritis. Autoimmun Rev. 2012;11:297-300. doi: 10.1016/j.autrev.2010.02.015</mixed-citation><mixed-citation xml:lang="en">Mayerl C, Prelog M. Immunosenescence and juvenile idiopathic arthritis. Autoimmun Rev. 2012;11:297-300. doi: 10.1016/j.autrev.2010.02.015</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Beukelman T, Xie F, Lang Chen Baddley JW, Delzell E, Grijalva CG, et al. Rates of hospitalized bacterial infection associated with juvenile idiopathic arthritis and its treatment. Arthritis Rheum. 2012;64:2773-2780. doi: 10.1002/art.34458</mixed-citation><mixed-citation xml:lang="en">Beukelman T, Xie F, Lang Chen Baddley JW, Delzell E, Grijalva CG, et al. Rates of hospitalized bacterial infection associated with juvenile idiopathic arthritis and its treatment. Arthritis Rheum. 2012;64:2773-2780. doi: 10.1002/art.34458</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Atzeni F, Bendtzen K, Bobbio-Pallavicini F, Conti F, Cutolo M, Montecucco C, et al, Infections and treatment of patients with rheumatic diseases. Clin Exp Rheumatol. 2008;26(Suppl 48):S6773.</mixed-citation><mixed-citation xml:lang="en">Atzeni F, Bendtzen K, Bobbio-Pallavicini F, Conti F, Cutolo M, Montecucco C, et al, Infections and treatment of patients with rheumatic diseases. Clin Exp Rheumatol. 2008;26(Suppl 48):S6773.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Horneff G, De Bock F, Foeldvari I, Girschick HJ, Michels H, Moebius D, et al. Safety and efficacy of combination of etanercept and methotrexate compared to treatment with etanercept only in patients with juvenile idiopathic arthritis (JIA): Preliminary data from the German JIA Registry. Ann Rheum Dis. 2009;68(4):519-525. doi: 10.1136/ard.2007.087593</mixed-citation><mixed-citation xml:lang="en">Horneff G, De Bock F, Foeldvari I, Girschick HJ, Michels H, Moebius D, et al. Safety and efficacy of combination of etanercept and methotrexate compared to treatment with etanercept only in patients with juvenile idiopathic arthritis (JIA): Preliminary data from the German JIA Registry. Ann Rheum Dis. 2009;68(4):519-525. doi: 10.1136/ard.2007.087593</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Listing J, Strangfeld A, Kary S, Rau R, von Hinueber U, Stoyanova-Scholz M, et al, Infections in patients with rheumatoid arthritis treated with biologic agents. Arthritis Rheum. 2005;52:340312. doi: 10.1002/art.21386</mixed-citation><mixed-citation xml:lang="en">Listing J, Strangfeld A, Kary S, Rau R, von Hinueber U, Stoyanova-Scholz M, et al, Infections in patients with rheumatoid arthritis treated with biologic agents. Arthritis Rheum. 2005;52:340312. doi: 10.1002/art.21386</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Curtis JR, Patkar N, Xie A, Martin C, Allison JJ, Saag M, et al. Risk of serious bacterial infections among rheumatoid arthritis patients exposed to tumor necrosis factor a antagonists. Arthritis Rheum. 2007;56:112533. doi: 10.1002/art.22504</mixed-citation><mixed-citation xml:lang="en">Curtis JR, Patkar N, Xie A, Martin C, Allison JJ, Saag M, et al. Risk of serious bacterial infections among rheumatoid arthritis patients exposed to tumor necrosis factor a antagonists. Arthritis Rheum. 2007;56:112533. doi: 10.1002/art.22504</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Askling J, Fored CM, Brandt L Baecklund E, Bertilsson L, Cöster L, et al. Risk and case characteristics of tuberculosis in rheumatoid arthritis associated with tumor necrosis factor antagonists in Sweden. Arthritis Rheum. 2005;52:198692. doi: 10.1002/art.21137</mixed-citation><mixed-citation xml:lang="en">Askling J, Fored CM, Brandt L Baecklund E, Bertilsson L, Cöster L, et al. Risk and case characteristics of tuberculosis in rheumatoid arthritis associated with tumor necrosis factor antagonists in Sweden. Arthritis Rheum. 2005;52:198692. doi: 10.1002/art.21137</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Beukelman T, Xie F, Baddley JW, Chen L, Delzell E, Grijalva CG, et al. Incidence of selected opportunistic infections among children with juvenile idiopathic arthritis. Arthritis Rheum. 2013;65:1384-1389. doi: 10.1002/art.37866</mixed-citation><mixed-citation xml:lang="en">Beukelman T, Xie F, Baddley JW, Chen L, Delzell E, Grijalva CG, et al. Incidence of selected opportunistic infections among children with juvenile idiopathic arthritis. Arthritis Rheum. 2013;65:1384-1389. doi: 10.1002/art.37866</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Gomez-Reino JJ, Carmona L, Angel Descalzo M. Biobadaser Group. Risk of tuberculosis in patients treated with tumor necrosis factor antagonists due to incomplete prevention of reactivation of latent infection. Arthritis Rheum. 2007;57:75661. doi: 10.1002/art.22768</mixed-citation><mixed-citation xml:lang="en">Gomez-Reino JJ, Carmona L, Angel Descalzo M. Biobadaser Group. Risk of tuberculosis in patients treated with tumor necrosis factor antagonists due to incomplete prevention of reactivation of latent infection. Arthritis Rheum. 2007;57:75661. doi: 10.1002/art.22768</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Doran MF, Crowson CS, Pond GR, O’Fallon WM, Gabriel SE. Frequency of infection in patients with rheumatoid arthritis compared with controls: A population-based study. Arthritis Rheum. 2002;46:228793. doi: 10.1002/art.10524</mixed-citation><mixed-citation xml:lang="en">Doran MF, Crowson CS, Pond GR, O’Fallon WM, Gabriel SE. Frequency of infection in patients with rheumatoid arthritis compared with controls: A population-based study. Arthritis Rheum. 2002;46:228793. doi: 10.1002/art.10524</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Glück T, Kiefmann B, Grohmann M, Falk W, Straub RH, Schölmerich J. Immune status and risk for infection in patients receiving chronic immunosuppressive therapy. J Rheumatol. 2005;32:147380.</mixed-citation><mixed-citation xml:lang="en">Glück T, Kiefmann B, Grohmann M, Falk W, Straub RH, Schölmerich J. Immune status and risk for infection in patients receiving chronic immunosuppressive therapy. J Rheumatol. 2005;32:147380.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Ada G. Vaccines and vaccination. N Engl J Med. 2001;345:1042-1053. doi: 10.1056/NEJMra011223</mixed-citation><mixed-citation xml:lang="en">Ada G. Vaccines and vaccination. N Engl J Med. 2001;345:1042-1053. doi: 10.1056/NEJMra011223</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Gluck T, Muller-Ladner U. Vaccination in patients with chronic rheumatic or autoimmune diseases. Clin Infect Dis. 2008;46:145965. doi: 10.1086/587063</mixed-citation><mixed-citation xml:lang="en">Gluck T, Muller-Ladner U. Vaccination in patients with chronic rheumatic or autoimmune diseases. Clin Infect Dis. 2008;46:145965. doi: 10.1086/587063</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Conti F, Rezai S, Valesini G. Vaccination and autoimmune rheumatic diseases. Autoimmun Rev. 2008;8:1248. doi: 10.1016/j.autrev.2008.07.007</mixed-citation><mixed-citation xml:lang="en">Conti F, Rezai S, Valesini G. Vaccination and autoimmune rheumatic diseases. Autoimmun Rev. 2008;8:1248. doi: 10.1016/j.autrev.2008.07.007</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Davies K, Woo P. Immunization in rheumatic diseases of childhood: An audit of the clinical practice of British Paediatric Rheumatology Group members and a review of the evidence. Rheumatology. 2002;41:93741. doi: 10.1093/rheumatology/41.8.937</mixed-citation><mixed-citation xml:lang="en">Davies K, Woo P. Immunization in rheumatic diseases of childhood: An audit of the clinical practice of British Paediatric Rheumatology Group members and a review of the evidence. Rheumatology. 2002;41:93741. doi: 10.1093/rheumatology/41.8.937</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Furer V, Rondaan C, Heijstek MW, Agmon-Levin N, van Assen S, Bijl M, et al. 2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis. 2020;79(1):39-52. doi: 10.1136/annrheumdis-2019-215882</mixed-citation><mixed-citation xml:lang="en">Furer V, Rondaan C, Heijstek MW, Agmon-Levin N, van Assen S, Bijl M, et al. 2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis. 2020;79(1):39-52. doi: 10.1136/annrheumdis-2019-215882</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">World Health Organization. Immunization coverage. 6 December 2019. URL: https://www.who.int/news-room/fact-sheets/detail/immunization-coverage (Accessed: DD Month YEAR).</mixed-citation><mixed-citation xml:lang="en">World Health Organization. Immunization coverage. 6 December 2019. URL: https://www.who.int/news-room/fact-sheets/detail/immunization-coverage (Accessed: DD Month YEAR).</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Vazhappilly S, Vanderkooi O, Benseler S, Gerschman T, Johnson N, Luca N, et al. Immunization status and barriers in childhood rheumatic diseases. American College of Rheumatology Association of Rheumatology Health Professionals Annual Meeting. 2014. URL: https://acrabstracts.org/abstract/immunization-status-and-barriers-inchildhood-rheumatic-diseases (Accessed: DD Month YEAR).</mixed-citation><mixed-citation xml:lang="en">Vazhappilly S, Vanderkooi O, Benseler S, Gerschman T, Johnson N, Luca N, et al. Immunization status and barriers in childhood rheumatic diseases. American College of Rheumatology Association of Rheumatology Health Professionals Annual Meeting. 2014. URL: https://acrabstracts.org/abstract/immunization-status-and-barriers-inchildhood-rheumatic-diseases (Accessed: DD Month YEAR).</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Petty RE, Southwood TR, Manners P, Baum J, Glass DN, Goldenberg J, et al. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: Second revision, Edmonton, 2001. J Rheumatol. 2004;31:390-392.</mixed-citation><mixed-citation xml:lang="en">Petty RE, Southwood TR, Manners P, Baum J, Glass DN, Goldenberg J, et al. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: Second revision, Edmonton, 2001. J Rheumatol. 2004;31:390-392.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Riaz A, Husain S, Yousafzai MT, Nisar I, Shaheen F, Mahesar W, et al. Reasons for non-vaccination and incomplete vaccinations among children in Pakistan. Vaccine. 2018;36(35):5288-5293. doi: 10.1016/j.vaccine.2018.07.024</mixed-citation><mixed-citation xml:lang="en">Riaz A, Husain S, Yousafzai MT, Nisar I, Shaheen F, Mahesar W, et al. Reasons for non-vaccination and incomplete vaccinations among children in Pakistan. Vaccine. 2018;36(35):5288-5293. doi: 10.1016/j.vaccine.2018.07.024</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">De Serres G, Desai S, Shane A, Hiebert J, Ouakki M, Severini A. Measles in Canada between 2002 and 2013. Open Forum Infect Dis. 2015;15:ofv048. doi: 10.1093/ofid/ofv048</mixed-citation><mixed-citation xml:lang="en">De Serres G, Desai S, Shane A, Hiebert J, Ouakki M, Severini A. Measles in Canada between 2002 and 2013. Open Forum Infect Dis. 2015;15:ofv048. doi: 10.1093/ofid/ofv048</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Fathima S, Ferrato C, Lee BE, Simmonds K, Yan L, Mukhi SN, et al., Bordetella pertussis in sporadic and outbreak settings in Alberta, Canada, July 2004 – December 2012. BMC Infect Dis. 2014;14:48. doi: 10.1186/1471-2334-14-48</mixed-citation><mixed-citation xml:lang="en">Fathima S, Ferrato C, Lee BE, Simmonds K, Yan L, Mukhi SN, et al., Bordetella pertussis in sporadic and outbreak settings in Alberta, Canada, July 2004 – December 2012. BMC Infect Dis. 2014;14:48. doi: 10.1186/1471-2334-14-48</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Lo Vecchio A, Cambriglia MD, Fedele MC, Basile FW, Chiatto F, Miraglia Del Giudice M, et al. Determinants of low measles vaccination coverage in children living in an endemic area. Eur J Pediatr. 2019;178(2):243-251. doi: 10.1007/s00431-018-3289-5</mixed-citation><mixed-citation xml:lang="en">Lo Vecchio A, Cambriglia MD, Fedele MC, Basile FW, Chiatto F, Miraglia Del Giudice M, et al. Determinants of low measles vaccination coverage in children living in an endemic area. Eur J Pediatr. 2019;178(2):243-251. doi: 10.1007/s00431-018-3289-5</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Gilbert NL, Gilmour H, Wilson SE, Cantin L. Determinants of non-vaccination and incomplete vaccination in Canadian toddlers. Hum Vaccin Immunother. 2017;13(6):1-7. doi: 10.1080/21645515.2016.1277847</mixed-citation><mixed-citation xml:lang="en">Gilbert NL, Gilmour H, Wilson SE, Cantin L. Determinants of non-vaccination and incomplete vaccination in Canadian toddlers. Hum Vaccin Immunother. 2017;13(6):1-7. doi: 10.1080/21645515.2016.1277847</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Marshall BC, Henshaw C, Evans DA, Bleyl K, Alder S, Liou TG. Influenza vaccination coverage level at a cystic fibrosis center. Pediatrics. 2002;109(5):E80-0. doi: 10.1542/peds.109.5.e80</mixed-citation><mixed-citation xml:lang="en">Marshall BC, Henshaw C, Evans DA, Bleyl K, Alder S, Liou TG. Influenza vaccination coverage level at a cystic fibrosis center. Pediatrics. 2002;109(5):E80-0. doi: 10.1542/peds.109.5.e80</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Lim C, Currie GE, Waddington CS, Wu Y, Setijo S, Leask J, et al. Identification of the determinants of incomplete vaccination in Australian children. Vaccine X. 2019;1:100010. doi: 10.1016/j.jvacx.2019.100010</mixed-citation><mixed-citation xml:lang="en">Lim C, Currie GE, Waddington CS, Wu Y, Setijo S, Leask J, et al. Identification of the determinants of incomplete vaccination in Australian children. Vaccine X. 2019;1:100010. doi: 10.1016/j.jvacx.2019.100010</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Morin MP, Quach C, Fortin E, Chédeville G. Vaccination coverage in children with juvenile idiopathic arthritis followed at a paediatric tertiary care centre. Rheumatology (Oxford). 2012;51(11):2046-2050. doi: 10.1093/rheumatology/kes175</mixed-citation><mixed-citation xml:lang="en">Morin MP, Quach C, Fortin E, Chédeville G. Vaccination coverage in children with juvenile idiopathic arthritis followed at a paediatric tertiary care centre. Rheumatology (Oxford). 2012;51(11):2046-2050. doi: 10.1093/rheumatology/kes175</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Bizjak M, Blazina Š, Zajc Avramovič M, Markelj G, Avčin T, Toplak N. Vaccination coverage in children with rheumatic diseases. Clin Exp Rheumatol. 2020;38(1):164-170.</mixed-citation><mixed-citation xml:lang="en">Bizjak M, Blazina Š, Zajc Avramovič M, Markelj G, Avčin T, Toplak N. Vaccination coverage in children with rheumatic diseases. Clin Exp Rheumatol. 2020;38(1):164-170.</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Намазова-Баранова ЛС, Валиева СИ, Федосеенко МВ, Новикова ДА, Ткаченко НЕ, Гайворонская АГ, и др. Анализ вакцинального статуса у пациентов с ювенильным идиопатическим артритом. Педиатрическая фармакология. 2016;13(4):334-339. doi: 10.15690/pf.v13i4.1604</mixed-citation><mixed-citation xml:lang="en">Namazova-Baranova LS, Valieva SI, Fedoseenko MV, Novikova DA, Tkachenko NE, Gaivoronskaya AG, et al. Analysis of the juvenile idiopathic arthritis immunization schedule. Pediatric Pharmacology. 2016;13(4):334-339 (In Russ.). doi: 10.15690/pf.v13i4.1604</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Kaufman J, Ryan R, Walsh L, Hill S, Horey D, Willis N, et al., Face-to-face interventions for informing or educating parents about early childhood vaccination. Cochrane Database Syst Rev. 2018;5:CD010038. doi: 10.1002/14651858.CD010038.pub3</mixed-citation><mixed-citation xml:lang="en">Kaufman J, Ryan R, Walsh L, Hill S, Horey D, Willis N, et al., Face-to-face interventions for informing or educating parents about early childhood vaccination. Cochrane Database Syst Rev. 2018;5:CD010038. doi: 10.1002/14651858.CD010038.pub3</mixed-citation></citation-alternatives></ref><ref id="cit32"><label>32</label><citation-alternatives><mixed-citation xml:lang="ru">Heijstek MW, Ott de Bruin LM, Bijl M, Borrow R, van der Klis F, Koné-Paut I, et al. EULAR recommendations for vaccination in paediatric patients with rheumatic diseases. Ann Rheum Dis. 2011;70:1704-1712. doi: 10.1136/ard.2011.150193</mixed-citation><mixed-citation xml:lang="en">Heijstek MW, Ott de Bruin LM, Bijl M, Borrow R, van der Klis F, Koné-Paut I, et al. EULAR recommendations for vaccination in paediatric patients with rheumatic diseases. Ann Rheum Dis. 2011;70:1704-1712. doi: 10.1136/ard.2011.150193</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
